Cytosorbents Cor (CTSO)

$CTSO fwiw The international, prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients https://link.springer.com/content/pdf/10.1186/s44158-026-00362-2_reference.pdf

$CTSO It is my understanding that CTSO has until March 31, 2026 to have its share price exceed $1/share for 10 consecutive days to avoid delisting. Of course, they can submit a compliance plan and request a 180 day extension. I believe that they will have to submit a compliance plan and would not be surprised if the compliance plan includes a proposal for a reverse stock split. We shall see shortly.

$CTSO hi is there any update/time line on the FDA clearance? Any feedback is more than welcome

$CTSO RSI: 68.75, MACD: 0.0147 Vol: 0.04, MA20: 0.67, MA50: 0.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$CTSO Dont they have to do a RS sometime soon. that is the main I stay away

Wall St is expecting -0.04 EPS for $CTSO Q1 [Reporting 05/05 AMC] http://www.estimize.com/intro/ctso?chart=historical&metric_name=eps&utm_c

$CTSO Current Stock Price: $0.64 Contracts to trade: $2.5 CTSO Feb 20 2026 Call Entry: $0.04 Exit: $0.05 ROI: 28% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$CTSO Obscure micro-cap; likely illiquid and speculative.

$CTSO we will see only movements if the FDA clearence is coming. This is key. I am still bullish

$CTSO Looks like CTSO closed at an all time low today. So sad. When will their BoD grow a pair and terminate the Company’s CEO?

$CTSO CytoSorbents initiated a proactive reorganization of its German commercial team and sales approach in the first quarter of 2025, which caused temporary, expected sales disruptions. Team still not reconvert with further issues ahead IMHO . Do not expect turnaround this year. Middle management not comfortable with CHAN ? Will BOARD finally act??

$CTSO Cardiovascular medical device; competes in a well-established market.

$CTSO Phil Chan, the Company’s CEO has repeatedly made open market purchases over the past several years, many at prices far above the existing share price. Many would suggest that these purchases are a testament to his belief that the current share price does not reflect the future value of the Company. However, the fact that none of his Board members have been following his lead and making open market purchases with their own funds is perhaps even more telling!

Sudden, temporary vision loss is easy to dismiss, especially when it resolves quickly. But as a new article from NovaVision, the vision rehabilitation division of Vycor Medical, explains, it can be one of the earliest warning signs of an approaching stroke. A transient ischemic attack, or TIA, often produces brief vision changes, including dimming or complete loss of sight in one eye, that can signal something more serious ahead. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. The article explores how sudden vision changes can serve as early stroke warnings, what types of vision loss commonly follow a stroke, and what rehabilitation options are available. As the article notes: “If you experience sudden vision loss, whether in one eye or across part of your visual field, along with any other stroke-associated symptoms, seek medical attention immediately. Acting fast is the single most important thing you can do to reduce the impact of a stroke.” Read the full article here: https://novavision.com/vision-loss-as-a-warning-sign-of-stroke/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$CTSO -Buy Lows

$CTSO companies pay Zacks Small Cap Research (SCR) for research coverage, typically paying between $10,000 and $50,000 annually. This service provides independent research reports, investor relations, and other services for small- and micro-cap firms.

$CTSO On Friday, CTSO closed at an all time low, once again dipping below the share price at which Phil Chan made his last open market purchase. Tell me, what actions if any, would you want to see the Board of Directors take before you’d be willing to increase your CTSO holdings?

$CTSO “stuffing the channel “ to meet quarterly revenue targets could be risk? In the end of year audit such should be flushed out?

Vision changes after a stroke can develop gradually and go unnoticed during recovery. Vycor’s NovaVision division provides a free online visual field screening tool that help stroke survivors check for potential changes and support informed conversations with their healthcare providers. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. In a new blog post, Vycor discusses five practical reasons online screening can be valuable, including accessibility and convenience, as well as early awareness of issues. As the article notes: “Screening results give you concrete information to discuss with your healthcare team. Rather than describing vague concerns about your vision, you can share screening results that show specific patterns.” Read the entire article here: https://novavision.com/five-reasons-to-consider-online-visual-field-screening/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$CTSO: CytoSorbents Price Target Increased to $5.00 Based on Higher Than Expected Gross Margins https://buff.ly/8xeFDUu

$CTSO 09:00 on Jan. 12 2026 What Analysts Are Saying About CytoSorbents Stock #tradeideas

$CTSO 07:25 on Jan. 12 2026 CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75% #tradeideas